查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736515

全球子宫颈癌疫苗市场规模：按产品类型、分销管道和地区分類的范围和预测

Global Cervical Cancer Vaccine Market Size By Product Type (Gardasil, Gardasil 9, and Cervarix), By Distribution Channel (Hospitals, Government Entities, and Clinics), By Geography Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3个工作天内

价格
简介目录

子宫颈癌疫苗市场规模及预测

2024 年子宫颈癌疫苗市场规模价值 50.8 亿美元，预计到 2032 年将达到 144.8 亿美元，在 2026-2032 年预测期内的复合年增长率为 13.94%。

女性子宫颈癌发生率的上升尤其令人担忧，因为它是一种相当常见的癌症，并且可能是首要的死亡原因。子宫颈癌疫苗的市场驱动力是全球子宫颈癌盛行率的上升。全球特别是开发中国家宫颈癌患者数量的快速增加促使主要企业以低成本开发新疫苗。此外，子宫颈癌发生率的上升促使政府和非营利组织采取倡议提高人们对子宫颈癌控制和预防、 人类乳突病毒(HPV)疫苗的认识。全球子宫颈癌疫苗市场报告对市场进行了全面评估。它全面分析了关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素。

定义全球子宫颈癌疫苗市场

子宫颈癌是一种发生在女性子宫颈（子宫与阴道的开口）的癌症。子宫颈癌的早期症状包括阴道异常出血，例如性交后或月经期间出血。大多数的子宫颈癌病例是由一种名为人类乳突病毒的常见病毒引起。大约99%的子宫颈癌是由高危险型人类乳突病毒（HPV）感染引起的。如果感染在子宫颈内持续存在，HPV会导致子宫颈组织异常生长。因此，疣状组织的异常生长可能导致子宫颈癌。

子宫颈癌的治疗包括手术、放射治疗和化疗。根据世界卫生组织 (WHO) 的数据，子宫颈癌是全球女性第四大常见癌症。然而，预防措施可以降低全球子宫颈癌病例增加的风险。子宫颈癌疫苗在预防导致女性子宫颈癌的 HPV 感染方面发挥重要作用。 HPV人类乳突病毒(HPV)疫苗有助于保护人体免受致癌的人类乳突病毒 (HPV) 感染。

如果在女孩和妇女感染病毒之前接种，该疫苗可以预防大多数子宫颈癌。世界卫生组织 (WHO) 建议 11 岁或 12 岁的女孩透过美国免疫计画接种人类乳突病毒(HPV)疫苗。然而，该疫苗最早可以在 9 岁，即在发生任何性接触或接触 HPV 之前接种。根据美国疾病管制与预防中心 (CDC) 的建议， 人类乳突病毒(HPV)疫苗建议接种两剂，每剂间隔六个月。现在无需再遵循先前建议的三剂接种方案。

全球子宫颈癌疫苗市场概况

全球子宫颈癌病例不断增加，这可能会增加对子宫颈癌疫苗的需求。根据美国癌症协会的数据，2021年将诊断出14,480例新的侵袭性子宫颈癌病例。此外，约有4,290名女性将死于子宫颈癌，而子宫颈癌历来是美国女性癌症死亡的主要原因之一。子宫颈癌疫苗可提供针对HPV感染的终身特异性抗体。如果保护作用持久，且无需定期终身加强接种，子宫颈癌疫苗的有效性和可接受性将显着提高。因此，疫苗的有效性至关重要。

研究表明，目前尚未发现任何人类乳突病毒(HPV)疫苗导致死亡的案例，但存在一些副作用。这些副作用虽然轻微，但有可能成为市场的主要限制因素。美国癌症协会指出， 人类乳突病毒(HPV)疫苗可能会引起头痛、发烧、噁心和头晕。此外，在新兴和低度开发国家建立国家疫苗接种计划可以扩大全球子宫颈癌疫苗市场。

目录

第一章子宫颈癌疫苗全球市场介绍

  • 市场定义
  • 市场区隔
  • 调查时间表
  • 先决条件
  • 限制

第 2 章 已验证的市场研究调查方法

  • 资料探勘
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 业界专家的重要见解
  • 资料来源

第三章执行摘要

  • 市场概览
  • 生态测绘
  • 绝对的商机
  • 市场吸引力
  • 全球子宫颈癌疫苗市场区域分析
  • 全球子宫颈癌疫苗市场（按产品类型划分）（百万美元）
  • 全球子宫颈癌疫苗市场按通路划分（百万美元）
  • 未来市场机会
  • 世界市场结构
  • 产品生命线

第四章全球子宫颈癌疫苗市场展望

  • 全球水产养殖疫苗的演变
  • 驱动程式
    • 司机1
    • 司机2
  • 限制因素
    • 约束因素 1
    • 约束因素 2
  • 机会
    • 机会1
    • 机会2
  • 波特五力模型
  • 价值链分析
  • 定价分析
  • 宏观经济分析

第五章全球子宫颈癌疫苗市场（依产品类型）

  • 概述
  • Gardasil
  • Gardasil9
  • Cervarix

第六章全球子宫颈癌疫苗市场（依应用）

  • 概述
  • 医院
  • 政府
  • 诊所

7. 全球子宫颈癌疫苗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中东和非洲
    • 阿拉伯聯合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第八章全球子宫颈癌疫苗市场竞争格局

  • 概述
  • 各公司市场排名
  • 公司地理分布
  • 公司产业布局
  • ACE矩阵

第九章 公司简介

  • Merck & Co. Inc.
  • GlaxoSmithKline plc.
  • Sanofi
  • AstraZeneca PLC
  • Bristol

第十章 已验证的市场情报

  • 关于已验证的市场情报
  • 动态资料视觉化
简介目录
Product Code: 37338

Cervical Cancer Vaccine Market Size And Forecast

Cervical Cancer Vaccine Market size was valued at USD 5.08 Billion in 2024, and the market size will reach USD 14.48 Billion by 2032, growing at a CAGR of 13.94% from 2026 to 2032.

The rising rate of cervical cancer among women is of particular concern because it may be a significantly common form of cancer and the number one reason for death. Its increasing prevalence worldwide is a major driver for the Cervical Cancer Vaccine Market. The worldwide surge in the number of cervical cancer patients, especially in developing countries, has motivated key players to develop new vaccines at a low cost. Furthermore, the growing incidence of cervical cancer has provoked governments and non-profit organizations to take the initiative to raise awareness regarding the control & prevention of cervical cancer and HPV vaccinations. The Global Cervical Cancer Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Cervical Cancer Vaccine Market Definition

Cervical cancer is a type of cancer that occurs in the cervix of the female body, at the opening of the womb from the vagina. The early symptoms of cervical cancer include unusual vaginal bleeding, such as bleeding after sex or between periods. Almost all cases of cervical cancer are caused by a very common virus called human papillomavirus. Around 99% of all cervical cancer caused due to infection with high-risk human papillomaviruses (HPV). HPV develops an abnormal growth of the tissue at the cervix if the infection stays inside the cervix for a long time. Thus, certain abnormal growth of the tissues such as warts can lead to cancer in the cervix.

Treatments for cervical cancer include surgery, radiotherapy, and chemotherapy. According to the World Health Organization, Cervical cancer is the fourth most common type of cancer in women around the world. However preventive measures can reduce the risk of increasing positive cases around the world. Cervical cancer vaccination plays a vital role in the prevention of the HPV infection that causes cervical cancer in women. The HPV vaccine helps to protect the body against infection with human papillomavirus or HPV that results in causing cancers.

The vaccine can prevent most cases of cervical cancer if given before a girl or woman is exposed to the virus. The World Health Organization has recommended the HPV vaccine for girls ages 11 or 12 through national immunization programs. However, the vaccine can be given as early as age 9 before they have sexual contact and are exposed to HPV. According to the Centers for Disease Control and Prevention (CDC), it is recommended that patients receive two doses of HPV vaccine at intervals of six months. Nowadays, taking a three-dose schedule as previously directed is unnecessary.

Global Cervical Cancer Vaccine Market Overview

Cervical cancer cases are increasing globally, which may increase the demand for cervical vaccines. According to the American Cancer Society, 14,480 new cases of invasive cervical cancer will be diagnosed in the United States in 2021. Furthermore, around 4,290 women will die from cervical cancer, which was historically one of the leading causes of cancer death in American women. The Cervical Cancer Vaccine ensures the persistence of particular antibodies against HPV infection for the rest of one's life. The effectiveness and acceptability of the Cervical Cancer Vaccine would be considerably enhanced if the protection was long-lasting and did not require regular boosters throughout life. As a result, the efficiency of the vaccine is critical.

Although investigations and research have found no deaths associated with any HPV vaccine, there are some side effects. These are minor, but they have the potential to become a major market constraint. According to the American Cancer Society, the HPV vaccine might cause headaches, fevers, nausea, and dizziness. Furthermore, the establishment of a national immunization program in developing and underdeveloped nations can expand the global Cervical Cancer Vaccine Market.

Global Cervical Cancer Vaccine Market: Segmentation Analysis

The Global Cervical Cancer Vaccine Market is segmented Based on Product Type, Distribution Channel, And Geography.

Cervical Cancer Vaccine Market, By Product Type

  • Gardasil
  • Gardasil 9
  • Cervarix

Based on Product Type, the market is bifurcated into Gardasil, Gardasil 9, and Cervarix. Gardasil accounted for the largest market share in 2020 and is projected to grow at a CAGR of 14.42% during the forecast period. Gardasil is a human papillomavirus (HPV) vaccine. It is a suspension for injection that contains purified proteins for four types of human papillomavirus (types 6, 11, 16, and 18). It is available in vials or prefilled syringes. Gardasil is used in males and females from the age of nine years to protect against the following conditions caused by specific types of human papillomavirus (HPV) such as precancerous lesions (growths) in the cervix, vulva or vagina and anus; cervical and anal cancers; genital warts.

Cervical Cancer Vaccine Market, By Application

  • Hospitals
  • Government Entities
  • Clinics

Based on the Application, the market has been segmented into Hospitals, Government Entities, and Clinics. Hospitals accounted for the largest market share in 2020 and are projected to grow at the highest CAGR of 14.65% during the forecast period. Government Entities was the second-largest market in 2020, and it is projected to grow at the highest CAGR.

Cervical Cancer Vaccine Market, By Geography

  • Asia Pacific
  • Middle East & Africa
  • Latin America

Based on Geography, the market is classified into Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific accounted for the largest market share and the Middle East & Africa was the second-largest market in 2020. Asia's economy continues to grow steadily, with strong progress in trading. The region is one of the leading and fastest-growing economies in the global market. The Asia Pacific region is likely to witness the highest growth in the global cervical cancer vaccine market over the forecast period owing to the extension of the already strong biologics market in the region, and the availability of screening tests and vaccine development potential as well.

Key Players

The "Global Cervical Cancer Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co. Inc., GlaxoSmithKline plc., Sanofi, AstraZeneca PLC, Bristol, and Others.

  • The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In February 2021, Merck acquired Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.
  • In June 2021, Sanofi partnered with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor-positive breast cancer.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL CERVICAL CANCER VACCINE MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Cervical Cancer Vaccine Market Geographical Analysis (CAGR %)
  • 3.6 Global Cervical Cancer Vaccine Market, By Product Type (USD Million)
  • 3.7 Global Cervical Cancer Vaccine Market, By Distribution Channel (USD Million)
  • 3.8 Future Market Opportunities
  • 3.9 Global Market Split
  • 3.10 Product Life Line

4 GLOBAL CERVICAL CANCER VACCINE MARKET OUTLOOK

  • 4.1 Global Aquaculture Vaccines Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL CERVICAL CANCER VACCINE MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Gardasil
  • 5.3 Gardasil 9
  • 5.4 Cervarix

6 GLOBAL CERVICAL CANCER VACCINE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Government Entities
  • 6.4 Clinics

7 GLOBAL CERVICAL CANCER VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL CERVICAL CANCER VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Merck & Co. Inc.
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Development
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 GlaxoSmithKline plc.
    • 9.2.1 Company Overview
    • 9.2.2 Company Insights
    • 9.2.3 Product Benchmarking
    • 9.2.4 Key Development
  • 9.3 Sanofi
    • 9.3.1 Company Overview
    • 9.3.2 Company Insights
    • 9.3.3 Product Benchmarking
    • 9.3.4 Key Development
  • 9.4 AstraZeneca PLC
    • 9.4.1 Company Overview
    • 9.4.2 Company Insights
    • 9.4.3 Product Benchmarking
    • 9.4.4 Key Development
  • 9.5 Bristol
    • 9.5.1 Company Overview
    • 9.5.2 Company Insights
    • 9.5.3 Product Benchmarking
    • 9.5.4 Key Development

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization